Martin Low has founded or co-founded eight companies including Eradivir where he has been CEO since inception in March of 2020.  Prior to Eradivir he served as CEO for 9 years at On Target Labs, another biotech he co-founded.  Under his leadership two drugs were brought into the clinic with the lead drug successfully filed with the FDA for approval in ovarian cancer. Throughout his career he has been successful in raising funds and securing partnerships.  For On Target, he raised $90M and secured partnerships with several key Medtech companies.  Martin has introduced several products that have won awards from Business Week, The Thomas Edison Foundation and the Smithsonian Institute. Martin has degrees from Purdue University and Northwestern’s Kellogg Graduate School of Management.

Dr. Stew Low serves as the Chief Operating Officer at Eradivir Inc, overseeing toxicology, CMC, and clinical development. Prior to joining Eradivir, he co-founded and served as Chief Scientific Officer at Novosteo Inc, a pharmaceutical company focused on accelerating bone fracture repair. Novosteo was successfully acquired by Quince Therapeutics, a rare disease company. As Head of Discovery at Quince Therapeutics, Stew played a pivotal executive team role in developing treatments for bone diseases. He holds a B.S. in Microbiology from Brigham Young University and a Ph.D. in Bioengineering from the University of Utah.

Dr. Philip S. Low is the Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry at Purdue University.  Dr. Low has devoted over 45 years to developing novel drugs for treatment of human diseases and characterizing the structure, function and pathologies of the human red blood cell. He has published more than 500 scientific articles and has over 100 US patents/patents pending. Eight drugs stemming from his research are currently undergoing human clinical trials in the areas of: i) tumor-targeted drugs for the imaging and therapy of cancer, ii) a new therapy for malaria, iii) a novel treatment for sickle cell disease, iv) tumor-targeted fluorescent dyes for image-guided surgery of cancer, and v) novel imaging and therapeutic agents for inflammatory and autoimmune diseases. From his research he has founded or cofounded seven companies.  His initial company, Endocyte, sold to Novartis for $2.1B in 2018. Dr. Low has received an NIH MERIT Award, the American Chemical Society’s Award for Cancer Research (Sosnovsky Award), the American Association for Cancer Research’s (AACR) Award for Outstanding Chemistry in Cancer Research, both of Purdue’s awards for outstanding research (McCoy and Sigma Xi Awards), the University’s highest career achievement award (Morrill Award), and numerous other National and International awards. Dr. Low received his B.S. in Chemistry from Brigham Young University (1971) and his Ph.D. in Biochemistry from UCSD (1975).

Dr.  Srinivasarao is currently the Vice President of Discovery at Eradivir, Inc. He received his PhD in chemistry from Purdue University in the field of total synthesis of natural products. He has about 15 years of experience working with several small biotech companies as consultant and adviser for discovery chemistry. He oversees discovery projects at Eradivir and is actively developing targeted immunotherapies for the treatment of several viral infections such as the influenza, HIV, RSV and HBV. He has published >40 research articles and book chapters; and has >30 filed patents in the area of medicinal chemistry. 

Dr. Nielsen is vice president of research and development at Eradivir, overseeing the early discovery and preclinical development efforts for the pipeline of Eradivir. He has spent the last 12 years on early drug discovery and development. He is trained both as a chemist and a biologist using an interdisciplinary approach to design and discover next generation targeted therapeutics. Dr. Nielsen has successfully led R&D teams in academia at Brigham Young University, Max Planck Institute, and Purdue University and in industry at Biofire diagnostics, Novosteo and Quince therapeutics. Dr. Nielsen was part of an integral team that led to the translation of technology for Novosteo from discovery to acquisition by the publicly traded company Cortexyme. Two products he was part of the discovery team for are now FDA approved and marketed. Dr Nielsen has founded or co-founded 4 successful companies in 2 different industries.   He has published 27 peer reviewed journal articles and abstracts and is a primary inventor on 35 US and international patents/patents pending. Dr Nielsen has additionally presented at over 50 international and national scientific conferences and been awarded 38 academic and professional awards including the young investigator award from the American Society of Bone and Mineral Research. He earned a B.S. in Biochemistry and B.S. in Genetics and Biotechnology with a concentration in human disease from Brigham Young University and a PhD in Medicinal Chemistry and Molecular Pharmacology from Purdue University.

Dr. Niedrauer is the Director of Drug Development at Eradivir. After growing up in rural Texas in an off-the-grid family, Mary left home at age 15 to put herself through college while working odd jobs. She earned a B.S. in Chemistry at age 19 with no prior education and went on to serve as an engineer on a combat deployment as a Corporal with the US Army.  Following military service, Mary concurrently earned an MBA from Purdue Global and a joint PhD in Synthetic Organic Chemistry and Peptide Chemistry from Purdue University. Mary has several years of industry experience in managing CMC and preclinical programs for both small molecules and biologics, from the pre-IND stage through early clinical development. Mary is also experienced in pharmacokinetic modeling and data analysis. In her free time, Mary enjoys a variety of hobbies including ultra-endurance events, powerlifting, rock climbing, snowboarding, and mountain biking. 

Dr. Kanduluru, has extensive experience in academia and biotech industry with over 20 years in medicinal chemistry, targeted drug delivery and CMC fields. He has been involved in design and development of drugs for various diseases including cancer and inflammatory diseases. He was a key player in process optimization and technology transfer for manufacturing of various clinical and pre-clinical drug candidates. Dr. Kanduluru has published more than three dozen peer reviewed scientific articles, issued/pending patents, two book chapters/reviews and presented research in national/international conferences for his credit. Dr. Kanduluru also holds a position an associate editor, potential scientific reviewer for numerous journals and received numerous international and national recognitions. He graduated with PhD in organic chemistry from Sri Venkateswara University, India and further pursued postdoctoral studies in medicinal chemistry and chemical biology field in France and USA.

Aaron has been involved in clinical research since 2002, having worked his way up from research assistant to program manager in academia before pivoting to industry in 2014. He comes to Eradivir with a wealth of experience in operationalizing clinical trials, ranging from investigator-initiated pilot studies through global Phase 3 clinical programs (and everything in-between) at start-ups and big pharma. An alumnus of the University of Pennsylvania and La Salle University, he is proud to have notched several successful NDAs and spends his free time pretending to be a musician.